Latest Pharma Insights
Genmab’s Phase III Trifecta: Petosemtamab Halves Risk Of Death In Frontline Head And Neck
After positive Phase III readouts for Epkinly and Rina-S, Genmab reported that its EGFRxLGR5 bispecific petosemtamab plus Keytruda also succeeded in the first-line treatment of head and neck squamous cell carcinoma.
Scrip - October 28, 2026
After positive Phase III readouts for Epkinly and Rina-S, Genmab reported that its EGFRxLGR5 bispecific petosemtamab plus Keytruda also succeeded in the first-line treatment of head and neck squamous cell carcinoma.
Scrip - October 28, 2026
Alzheimer’s Blood Tests Need Clearer Primary Care Guidance, AdvaMed Panelists Say
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four experts discussed the clinical, technological and policy challenges in implementing blood-based biomarkers for the disease at the AdvaMed MedTech Conference.
Medtech Insight - October 28, 2026
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four experts discussed the clinical, technological and policy challenges in implementing blood-based biomarkers for the disease at the AdvaMed MedTech Conference.
Medtech Insight - October 28, 2026
Geron’s Rytelo Expansion Into Myelofibrosis Thwarted As Trial Discontinued
The biotech said it would halt a myelofibrosis trial of Rytelo in myelofibrosis after the determination it would not meet its primary endpoint, leaving it with only the myelodysplastic syndromes indication.
Scrip - October 28, 2026
The biotech said it would halt a myelofibrosis trial of Rytelo in myelofibrosis after the determination it would not meet its primary endpoint, leaving it with only the myelodysplastic syndromes indication.
Scrip - October 28, 2026
Astellas Looks To Audax Preclinical Candidate For Targeted IL-12 Activation
Deal Snapshot: Having identified immuno-oncology as one of its priority R&D areas, Astellas gets global option rights to a preclinical IL-12 antibody-cytokine fusion candidate for solid tumors.
Scrip - October 28, 2026
Deal Snapshot: Having identified immuno-oncology as one of its priority R&D areas, Astellas gets global option rights to a preclinical IL-12 antibody-cytokine fusion candidate for solid tumors.
Scrip - October 28, 2026
GE HealthCare Moves To Own Radiopharma’s Last Mile As Flyrcado Targets SPECT Users
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado’s final-mile distribution, as the company bets that supply reliability — not just clinical demand — will determine how fast cardiac PET imaging displaces SPECT.
Medtech Insight - October 28, 2026
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado’s final-mile distribution, as the company bets that supply reliability — not just clinical demand — will determine how fast cardiac PET imaging displaces SPECT.
Medtech Insight - October 28, 2026
Chirp Innovations, Pro-Optics And Peter Schiff Enterprises Hit With FDA Warning Letters
The US Food and Drug Administration posted warning letters to three medical device manufacturers on Oct. 27, citing violations involving unapproved device marketing, product modifications, manufacturing controls and quality management systems.
Medtech Insight - October 28, 2026
The US Food and Drug Administration posted warning letters to three medical device manufacturers on Oct. 27, citing violations involving unapproved device marketing, product modifications, manufacturing controls and quality management systems.
Medtech Insight - October 28, 2026
ESMO 2026: Orpathys Combo Gives MET-Resistant Tagrisso NSCLC Patients A Chemo-Free Option
AstraZeneca’s Tagrisso can be used with the MET inhibitor Orpathys to reduce the risk of disease progression and death in some patients after they have already progressed on Tagrisso alone. The new SAFFRON study data should strengthen the UK major’s position in EGFR mutated lung cancer.
Scrip - October 28, 2026
AstraZeneca’s Tagrisso can be used with the MET inhibitor Orpathys to reduce the risk of disease progression and death in some patients after they have already progressed on Tagrisso alone. The new SAFFRON study data should strengthen the UK major’s position in EGFR mutated lung cancer.
Scrip - October 28, 2026
GSK Has Last Laugh Over Critics As Cancer Portfolio Flourishes
A couple of years ago, laughter would have greeted claims that the company would soon have a number of potential best-in-class oncology assets, CEO Luke Miels said on GSK's Q3 call. Not so now.
Scrip - October 28, 2026
A couple of years ago, laughter would have greeted claims that the company would soon have a number of potential best-in-class oncology assets, CEO Luke Miels said on GSK's Q3 call. Not so now.
Scrip - October 28, 2026
‘Synchronized Swimming’ Must Wait, But FDA And EMA Ready To Collaborate On Botanical Drug Regulation
FDA and EMA say they could start collaboration on herbal and botanical drug regulation with batch-to-batch quality variation and herb-drug interactions. Industry sees adopting real-world evidence as key, but says harmonizing the two very different regulatory regimes is a long way off.
HBW Insight - October 28, 2026
FDA and EMA say they could start collaboration on herbal and botanical drug regulation with batch-to-batch quality variation and herb-drug interactions. Industry sees adopting real-world evidence as key, but says harmonizing the two very different regulatory regimes is a long way off.
HBW Insight - October 28, 2026
Cipla Reiterates $1bn FY27 US Guidance Despite Lanreotide Woes As Ipsen Extends Gains
Cipla’s lanreotide supply disruption is seen continuing through FY27 as Pharmathen’s Greece unit is still on FDA’s October import alert list, but Cipla has reiterated a $1bn US sales guidance on the back of planned respiratory and peptide product launches.
Generics Bulletin - October 28, 2026
Cipla’s lanreotide supply disruption is seen continuing through FY27 as Pharmathen’s Greece unit is still on FDA’s October import alert list, but Cipla has reiterated a $1bn US sales guidance on the back of planned respiratory and peptide product launches.
Generics Bulletin - October 28, 2026
Bio-Thera Announces Chinese Approval For The First Secukinumab Biosimilar
Chinese regulator, the National Medical Products Administration (NMPA) has granted marketing approval for Bio-Thera's BAT2306, the first secukinumab biosimilar to be approved by any regulator worldwide, the company said.
Generics Bulletin - October 28, 2026
Chinese regulator, the National Medical Products Administration (NMPA) has granted marketing approval for Bio-Thera's BAT2306, the first secukinumab biosimilar to be approved by any regulator worldwide, the company said.
Generics Bulletin - October 28, 2026
Celltrion Secures Major US Deals For Xolair Biosimilar Weeks After Launch
Celltrion’s youngest US commercial biosimilar Omlyclo (omalizumab-igec) has already secured deals within weeks of its launch, with other young products continuing to drive the firm’s financial performance.
Generics Bulletin - October 28, 2026
Celltrion’s youngest US commercial biosimilar Omlyclo (omalizumab-igec) has already secured deals within weeks of its launch, with other young products continuing to drive the firm’s financial performance.
Generics Bulletin - October 28, 2026
Locked Out? How Countries That Are Slow To Adopt Biosimilar Streamlining May Miss Out On Savings
At last week’s biosimilars webinar hosted by the IGBA, Robert Russell-Pavier of Medicines UK spoke about how countries that do not follow the trend of biosimilar streamlining could lose out on savings – and how the UK is both driving uptake but also risking making itself unattractive via low prices.
Generics Bulletin - October 28, 2026
At last week’s biosimilars webinar hosted by the IGBA, Robert Russell-Pavier of Medicines UK spoke about how countries that do not follow the trend of biosimilar streamlining could lose out on savings – and how the UK is both driving uptake but also risking making itself unattractive via low prices.
Generics Bulletin - October 28, 2026
Mankind’s Growth Strategy Puts Chronic Drugs, Specialty Portfolio In Focus
Mankind’s 50% chronic-therapy ambition sets direction for how it plans to reshape its domestic business.
Generics Bulletin - October 28, 2026
Mankind’s 50% chronic-therapy ambition sets direction for how it plans to reshape its domestic business.
Generics Bulletin - October 28, 2026
Nucleai’s ‘Tissue Intelligence’ Transforms ADC Drug Trials
Nucleai’s AI maps cells in pathology slides to explain why ADCs fail some patients, aiming to predict responders before trials, with Gilead its named partner.
In Vivo - October 28, 2026
Nucleai’s AI maps cells in pathology slides to explain why ADCs fail some patients, aiming to predict responders before trials, with Gilead its named partner.
In Vivo - October 28, 2026
ESMO 2026: Ris-Rez Offers First Progress In Osteosarcoma For Decades
A Phase III trial of GSK and Hansoh's risvutatug rezetecan delivered a 67% reduction in the risk of disease progression or death, demonstrating the benefits of the B7-H3-directed antibody-drug conjugate in relapsed osteosarcoma.
Scrip - October 28, 2026
A Phase III trial of GSK and Hansoh's risvutatug rezetecan delivered a 67% reduction in the risk of disease progression or death, demonstrating the benefits of the B7-H3-directed antibody-drug conjugate in relapsed osteosarcoma.
Scrip - October 28, 2026
APAC Recap: Asia Drafts AI Device Criteria, India Bans Device Reuse And Markups Draw Scrutiny
China, Japan and Korea issued AI device documents, Australia applied device rules to AI scribes, and Singapore widened reliance but left devices out of its HTA fast lane. India moved against hospital consumable markups and banned reuse of single-use devices.
Medtech Insight - October 28, 2026
China, Japan and Korea issued AI device documents, Australia applied device rules to AI scribes, and Singapore widened reliance but left devices out of its HTA fast lane. India moved against hospital consumable markups and banned reuse of single-use devices.
Medtech Insight - October 28, 2026
ESMO 2026: Henlius Builds US SCLC Franchise On Solid Tecentriq Comparator Results
Supported by numerical superiority over Roche’s Tecentriq from a US-based bridging study, Henlius's serplulimab will help the Chinese firm build out a franchise in small cell lung cancer in the US and beyond.
Scrip - October 28, 2026
Supported by numerical superiority over Roche’s Tecentriq from a US-based bridging study, Henlius's serplulimab will help the Chinese firm build out a franchise in small cell lung cancer in the US and beyond.
Scrip - October 28, 2026
Nanexa’s Atomic Shell Game: How ALD Tech Landed A Novo Deal Worth Up To €1.165bn
Nanexa’s CEO said PharmaShell’s ALD-coated particles could stretch GLP-1 dosing to monthly or quarterly, but its semaglutide data are rat-based and simulated. Novo’s license, worth up to €1.165bn, and a Forge Nano scale-up deal frame what comes next, including combination-product questions.
Medtech Insight - October 28, 2026
Nanexa’s CEO said PharmaShell’s ALD-coated particles could stretch GLP-1 dosing to monthly or quarterly, but its semaglutide data are rat-based and simulated. Novo’s license, worth up to €1.165bn, and a Forge Nano scale-up deal frame what comes next, including combination-product questions.
Medtech Insight - October 28, 2026
ESMO 2026: Hengrui ADC Meets PFS Endpoints In HER2-Low Breast Cancer
Jiangsu Hengrui’s anti-HER2 ADC trastuzumab rezetecan reduced the risk of disease progression by 73% in a China-only Phase III trial in HER2-low metastatic breast cancer.
Scrip - October 28, 2026
Jiangsu Hengrui’s anti-HER2 ADC trastuzumab rezetecan reduced the risk of disease progression by 73% in a China-only Phase III trial in HER2-low metastatic breast cancer.
Scrip - October 28, 2026
GMP Violations Snag Rohto Eye Drop Plant In Vietnam, OTC Biologics Sales Trip Malaysian Firm
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Genmab’s Phase III Trifecta: Petosemtamab Halves Risk Of Death In Frontline Head And Neck
After positive Phase III readouts for Epkinly and Rina-S, Genmab reported that its EGFRxLGR5 bispecific petosemtamab plus Keytruda also succeeded in the first-line treatment of head and neck squamous cell carcinoma.
Scrip - October 28, 2026
After positive Phase III readouts for Epkinly and Rina-S, Genmab reported that its EGFRxLGR5 bispecific petosemtamab plus Keytruda also succeeded in the first-line treatment of head and neck squamous cell carcinoma.
Scrip - October 28, 2026
Geron’s Rytelo Expansion Into Myelofibrosis Thwarted As Trial Discontinued
The biotech said it would halt a myelofibrosis trial of Rytelo in myelofibrosis after the determination it would not meet its primary endpoint, leaving it with only the myelodysplastic syndromes indication.
Scrip - October 28, 2026
The biotech said it would halt a myelofibrosis trial of Rytelo in myelofibrosis after the determination it would not meet its primary endpoint, leaving it with only the myelodysplastic syndromes indication.
Scrip - October 28, 2026
Astellas Looks To Audax Preclinical Candidate For Targeted IL-12 Activation
Deal Snapshot: Having identified immuno-oncology as one of its priority R&D areas, Astellas gets global option rights to a preclinical IL-12 antibody-cytokine fusion candidate for solid tumors.
Scrip - October 28, 2026
Deal Snapshot: Having identified immuno-oncology as one of its priority R&D areas, Astellas gets global option rights to a preclinical IL-12 antibody-cytokine fusion candidate for solid tumors.
Scrip - October 28, 2026
ESMO 2026: Orpathys Combo Gives MET-Resistant Tagrisso NSCLC Patients A Chemo-Free Option
AstraZeneca’s Tagrisso can be used with the MET inhibitor Orpathys to reduce the risk of disease progression and death in some patients after they have already progressed on Tagrisso alone. The new SAFFRON study data should strengthen the UK major’s position in EGFR mutated lung cancer.
Scrip - October 28, 2026
AstraZeneca’s Tagrisso can be used with the MET inhibitor Orpathys to reduce the risk of disease progression and death in some patients after they have already progressed on Tagrisso alone. The new SAFFRON study data should strengthen the UK major’s position in EGFR mutated lung cancer.
Scrip - October 28, 2026
GSK Has Last Laugh Over Critics As Cancer Portfolio Flourishes
A couple of years ago, laughter would have greeted claims that the company would soon have a number of potential best-in-class oncology assets, CEO Luke Miels said on GSK's Q3 call. Not so now.
Scrip - October 28, 2026
A couple of years ago, laughter would have greeted claims that the company would soon have a number of potential best-in-class oncology assets, CEO Luke Miels said on GSK's Q3 call. Not so now.
Scrip - October 28, 2026
ESMO 2026: Ris-Rez Offers First Progress In Osteosarcoma For Decades
A Phase III trial of GSK and Hansoh's risvutatug rezetecan delivered a 67% reduction in the risk of disease progression or death, demonstrating the benefits of the B7-H3-directed antibody-drug conjugate in relapsed osteosarcoma.
Scrip - October 28, 2026
A Phase III trial of GSK and Hansoh's risvutatug rezetecan delivered a 67% reduction in the risk of disease progression or death, demonstrating the benefits of the B7-H3-directed antibody-drug conjugate in relapsed osteosarcoma.
Scrip - October 28, 2026
ESMO 2026: Henlius Builds US SCLC Franchise On Solid Tecentriq Comparator Results
Supported by numerical superiority over Roche’s Tecentriq from a US-based bridging study, Henlius's serplulimab will help the Chinese firm build out a franchise in small cell lung cancer in the US and beyond.
Scrip - October 28, 2026
Supported by numerical superiority over Roche’s Tecentriq from a US-based bridging study, Henlius's serplulimab will help the Chinese firm build out a franchise in small cell lung cancer in the US and beyond.
Scrip - October 28, 2026
ESMO 2026: Hengrui ADC Meets PFS Endpoints In HER2-Low Breast Cancer
Jiangsu Hengrui’s anti-HER2 ADC trastuzumab rezetecan reduced the risk of disease progression by 73% in a China-only Phase III trial in HER2-low metastatic breast cancer.
Scrip - October 28, 2026
Jiangsu Hengrui’s anti-HER2 ADC trastuzumab rezetecan reduced the risk of disease progression by 73% in a China-only Phase III trial in HER2-low metastatic breast cancer.
Scrip - October 28, 2026
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Alzheimer’s Blood Tests Need Clearer Primary Care Guidance, AdvaMed Panelists Say
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four experts discussed the clinical, technological and policy challenges in implementing blood-based biomarkers for the disease at the AdvaMed MedTech Conference.
Medtech Insight - October 28, 2026
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four experts discussed the clinical, technological and policy challenges in implementing blood-based biomarkers for the disease at the AdvaMed MedTech Conference.
Medtech Insight - October 28, 2026
GE HealthCare Moves To Own Radiopharma’s Last Mile As Flyrcado Targets SPECT Users
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado’s final-mile distribution, as the company bets that supply reliability — not just clinical demand — will determine how fast cardiac PET imaging displaces SPECT.
Medtech Insight - October 28, 2026
GE HealthCare is buying SOFIE Biosciences to take direct control of Flyrcado’s final-mile distribution, as the company bets that supply reliability — not just clinical demand — will determine how fast cardiac PET imaging displaces SPECT.
Medtech Insight - October 28, 2026
Chirp Innovations, Pro-Optics And Peter Schiff Enterprises Hit With FDA Warning Letters
The US Food and Drug Administration posted warning letters to three medical device manufacturers on Oct. 27, citing violations involving unapproved device marketing, product modifications, manufacturing controls and quality management systems.
Medtech Insight - October 28, 2026
The US Food and Drug Administration posted warning letters to three medical device manufacturers on Oct. 27, citing violations involving unapproved device marketing, product modifications, manufacturing controls and quality management systems.
Medtech Insight - October 28, 2026
APAC Recap: Asia Drafts AI Device Criteria, India Bans Device Reuse And Markups Draw Scrutiny
China, Japan and Korea issued AI device documents, Australia applied device rules to AI scribes, and Singapore widened reliance but left devices out of its HTA fast lane. India moved against hospital consumable markups and banned reuse of single-use devices.
Medtech Insight - October 28, 2026
China, Japan and Korea issued AI device documents, Australia applied device rules to AI scribes, and Singapore widened reliance but left devices out of its HTA fast lane. India moved against hospital consumable markups and banned reuse of single-use devices.
Medtech Insight - October 28, 2026
Nanexa’s Atomic Shell Game: How ALD Tech Landed A Novo Deal Worth Up To €1.165bn
Nanexa’s CEO said PharmaShell’s ALD-coated particles could stretch GLP-1 dosing to monthly or quarterly, but its semaglutide data are rat-based and simulated. Novo’s license, worth up to €1.165bn, and a Forge Nano scale-up deal frame what comes next, including combination-product questions.
Medtech Insight - October 28, 2026
Nanexa’s CEO said PharmaShell’s ALD-coated particles could stretch GLP-1 dosing to monthly or quarterly, but its semaglutide data are rat-based and simulated. Novo’s license, worth up to €1.165bn, and a Forge Nano scale-up deal frame what comes next, including combination-product questions.
Medtech Insight - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
‘Synchronized Swimming’ Must Wait, But FDA And EMA Ready To Collaborate On Botanical Drug Regulation
FDA and EMA say they could start collaboration on herbal and botanical drug regulation with batch-to-batch quality variation and herb-drug interactions. Industry sees adopting real-world evidence as key, but says harmonizing the two very different regulatory regimes is a long way off.
HBW Insight - October 28, 2026
FDA and EMA say they could start collaboration on herbal and botanical drug regulation with batch-to-batch quality variation and herb-drug interactions. Industry sees adopting real-world evidence as key, but says harmonizing the two very different regulatory regimes is a long way off.
HBW Insight - October 28, 2026
GMP Violations Snag Rohto Eye Drop Plant In Vietnam, OTC Biologics Sales Trip Malaysian Firm
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Cipla Reiterates $1bn FY27 US Guidance Despite Lanreotide Woes As Ipsen Extends Gains
Cipla’s lanreotide supply disruption is seen continuing through FY27 as Pharmathen’s Greece unit is still on FDA’s October import alert list, but Cipla has reiterated a $1bn US sales guidance on the back of planned respiratory and peptide product launches.
Generics Bulletin - October 28, 2026
Cipla’s lanreotide supply disruption is seen continuing through FY27 as Pharmathen’s Greece unit is still on FDA’s October import alert list, but Cipla has reiterated a $1bn US sales guidance on the back of planned respiratory and peptide product launches.
Generics Bulletin - October 28, 2026
Bio-Thera Announces Chinese Approval For The First Secukinumab Biosimilar
Chinese regulator, the National Medical Products Administration (NMPA) has granted marketing approval for Bio-Thera's BAT2306, the first secukinumab biosimilar to be approved by any regulator worldwide, the company said.
Generics Bulletin - October 28, 2026
Chinese regulator, the National Medical Products Administration (NMPA) has granted marketing approval for Bio-Thera's BAT2306, the first secukinumab biosimilar to be approved by any regulator worldwide, the company said.
Generics Bulletin - October 28, 2026
Celltrion Secures Major US Deals For Xolair Biosimilar Weeks After Launch
Celltrion’s youngest US commercial biosimilar Omlyclo (omalizumab-igec) has already secured deals within weeks of its launch, with other young products continuing to drive the firm’s financial performance.
Generics Bulletin - October 28, 2026
Celltrion’s youngest US commercial biosimilar Omlyclo (omalizumab-igec) has already secured deals within weeks of its launch, with other young products continuing to drive the firm’s financial performance.
Generics Bulletin - October 28, 2026
Locked Out? How Countries That Are Slow To Adopt Biosimilar Streamlining May Miss Out On Savings
At last week’s biosimilars webinar hosted by the IGBA, Robert Russell-Pavier of Medicines UK spoke about how countries that do not follow the trend of biosimilar streamlining could lose out on savings – and how the UK is both driving uptake but also risking making itself unattractive via low prices.
Generics Bulletin - October 28, 2026
At last week’s biosimilars webinar hosted by the IGBA, Robert Russell-Pavier of Medicines UK spoke about how countries that do not follow the trend of biosimilar streamlining could lose out on savings – and how the UK is both driving uptake but also risking making itself unattractive via low prices.
Generics Bulletin - October 28, 2026
Mankind’s Growth Strategy Puts Chronic Drugs, Specialty Portfolio In Focus
Mankind’s 50% chronic-therapy ambition sets direction for how it plans to reshape its domestic business.
Generics Bulletin - October 28, 2026
Mankind’s 50% chronic-therapy ambition sets direction for how it plans to reshape its domestic business.
Generics Bulletin - October 28, 2026
Nucleai’s ‘Tissue Intelligence’ Transforms ADC Drug Trials
Nucleai’s AI maps cells in pathology slides to explain why ADCs fail some patients, aiming to predict responders before trials, with Gilead its named partner.
In Vivo - October 28, 2026
Nucleai’s AI maps cells in pathology slides to explain why ADCs fail some patients, aiming to predict responders before trials, with Gilead its named partner.
In Vivo - October 28, 2026